Welcome to Xi’an Good Doctor Medical Science and Technology Co., Ltd.website ！
Internet Drug Information Service Qualification Certificate: (Shaanxi)-Non-Operating -2023-0143
Reposted: Breakthrough Advances in Intraperitoneal Hyperthermic Perfusion for Gastrointestinal Surgery—Ultrasound-Guided Puncture and Catheter Placement Enables Precision Treatment of Chemotherapy-Resistant Peritoneal Mesothelioma
Peking University Hospital Taiyuan Hospital (Taiyuan Central Hospital), as a designated national regional medical center, has consistently spearheaded innovations in oncology diagnosis and treatment.
2026-06-24
Peking University Hospital Taiyuan Hospital (Taiyuan Central Hospital), as a designated national regional medical center, has consistently spearheaded innovations in oncology diagnosis and treatment within the region. Since December 2025, when it pioneered hyperthermic intraperitoneal chemotherapy (HIPEC) in Taiyuan, the technical team led by Director Liang Qizheng of the Department of Gastrointestinal Surgery and Associate Chief Physician Fan Yue has completed more than 60 HIPEC procedures, treating a wide range of intra-abdominal malignancies, including gastric cancer, colorectal cancer, small‑intestine tumors, appendiceal tumors, peritoneal cancer, pancreatic cancer, and ovarian cancer. All treatments were performed via catheter placement during surgical procedures, with HIPEC administered either intraoperatively or postoperatively. The procedures have been carried out smoothly, without serious complications, and have demonstrated significant clinical efficacy, offering patients with intra-abdominal malignancies a novel therapeutic option.
Breakthrough: From Intraoperative Surgery to Ultrasound-Guided Puncture
On June 11, 2026, the technology achieved a milestone breakthrough—its first application in patients with unresectable peritoneal mesothelioma.
Peritoneal mesothelioma is a rare, highly malignant neoplasm with a poor prognosis. Treatment is centered on cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), supplemented by multidisciplinary approaches including chemotherapy, targeted therapy, and immunotherapy. After being evaluated at several hospitals, this patient presented to the Oncology Department of Peking University First Hospital Taiyuan Branch. At the time of presentation, hepatic and mediastinal lymph node metastases were already evident, accompanied by malignant ascites, precluding the possibility of curative surgical resection. Conventional treatment options were limited, and the prognosis was extremely poor. The oncology team initiated a multidisciplinary team (MDT) approach: led by Dr. Wang Jun, Director of the Ultrasound Department, and comprising Chief Physician Lu Yueling from the Oncology Department and Associate Chief Physician Fan Yue from the Gastrointestinal Surgery Department, they jointly developed a tailored treatment plan. Under ultrasound guidance, they precisely performed peritoneal catheterization, followed by successful HIPEC administration without any adverse events.
This treatment has overcome the previous limitation of HIPEC, which relied on surgical placement of catheters, marking a significant advancement: the HIPEC technique at Peking University First Hospital Taiyuan Branch has expanded from an “intraoperative adjunctive therapy” to an “independent therapeutic modality for refractory intra-abdominal malignancies,” thereby opening a new avenue of hope for patients with peritoneal metastases and malignant peritoneal tumors who have lost the opportunity for surgery.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
The perfusion solution containing chemotherapeutic agents is heated to a specified temperature and continuously circulated at a constant temperature into the patient’s thoracic and abdominal cavities, maintained for a defined period. This approach leverages the synergistic sensitization effect of hyperthermic chemotherapy and mechanical flushing to eradicate residual cancer cells and microscopic lesions within the body cavity.
Technological Advantages: Why is HIPEC Worth Paying Attention To?
HIPEC involves heating a chemotherapy‑containing perfusate to 42–43°C and circulating it throughout the thoracic and abdominal cavities, thereby directly eradicating free cancer cells and microscopic metastases within these spaces. Its advantages include:
Precise thermotherapy–chemotherapy synergy: synergistic enhancement of treatment efficacy.
Local high concentration: Intraperitoneal drug concentrations can reach dozens of times those achieved with intravenous administration.
Low systemic side effects: reduces the toxic adverse reactions of systemic chemotherapy.
HIPEC intraperitoneal therapy
HIPEC thoracic treatment
HIPEC treatment by the gastrointestinal surgery team
Intraoperative hyperthermic intraperitoneal chemotherapy
Intraperitoneal Hyperthermic Perfusion After Surgery
In all treated cases, no severe adverse reactions or complications were observed; patients experienced effective control of ascites, reductions in tumor markers, and marked improvements in quality of life.
Key words:
Related News
· China Good Doctor ·
· Good friends of human beings ·
Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China
Copyright Xi'an Good Doctor Medical Technology Co., Ltd.
Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143